Sunscreen Pills: Does Polypodium Leucotomos Actually Protect You?

Here’s a claim that sounds too good to be true: take a pill every morning and get sun protection from the inside out. No white cast, no reapplication, no worrying about sweat wiping it off. Just a capsule of fern extract and you’re covered.

Polypodium leucotomos (PL) is a tropical fern that’s been sold as an oral photoprotective supplement for years. It shows up in dermatology waiting rooms, wellness influencer recommendations, and more than a few summer “routine refresh” posts. And unlike a lot of supplement trends, it actually has peer-reviewed research behind it.

The research just doesn’t say what the marketing implies.

What Polypodium Leucotomos Actually Is

Polypodium leucotomos is a fern native to Central and South America. The extract — typically sold under brand names like Heliocare or Fernblock — contains a mix of phenolic compounds, including caffeic acid, ferulic acid, and chlorogenic acid. Those are antioxidants, which is the key word here. They work by neutralizing free radicals generated by UV exposure, not by blocking UV rays at the skin surface.

This is a meaningful distinction. Topical sunscreen creates a physical or chemical barrier. An oral antioxidant does something different: it reduces the downstream oxidative damage that UV triggers inside your cells.

Think of it less like a shield and more like a cleanup crew.

What the Research Actually Shows

The clinical data on PL is real, and it’s been accumulating since the early 2000s. The general finding: oral PL supplementation measurably increases the minimum erythema dose (MED) — the amount of UV radiation needed to produce visible redness on the skin. A 2020 review published in the Journal of the American Academy of Dermatology summarized several randomized controlled trials and found PL consistently raised MED by around 20–50%, depending on dose, UV source, and individual variation.

In practical terms, that translates to roughly an SPF 3–4 equivalent. A meaningful bump. Not nothing.

There’s also reasonable evidence that PL helps with:

• Reducing UV-induced immunosuppression — UV doesn’t just burn skin, it temporarily suppresses local immune function. A few studies suggest PL blunts this effect.
• Photoprotection in photosensitive conditions — PL has been studied in polymorphic light eruption (a common sun allergy) and melasma, with modest but real results. If you’re dealing with melasma, it’s one of the few oral adjuncts a dermatologist might actually recommend.
• Reducing UV-induced DNA damage markers — some smaller studies found lower levels of cyclobutane pyrimidine dimers (a type of UV-induced DNA lesion) in PL-treated subjects. The clinical significance of this is still being worked out.

Where the evidence gets thin: long-term studies on actual cancer risk reduction don’t exist. The endpoints in most trials are short-term surrogates — MED, redness, biomarkers. Whether any of this translates to fewer squamous cell carcinomas 20 years from now, nobody knows.

The “Sunscreen in a Pill” Problem

Supplement companies marketing PL sometimes use the phrase “internal sunscreen” or imply it works like a sunscreen you’d apply to your face. It doesn’t.

SPF 3–4 is, clinically speaking, low protection. For context, SPF 15 blocks about 93% of UVB. SPF 3 blocks roughly 67%. That gap is significant when you’re spending a full day outdoors.

More importantly: PL appears to work primarily on UVB-driven endpoints like redness and MED. The data on UVA protection — the radiation responsible for photoaging, collagen breakdown, and a meaningful share of skin cancer risk — is less robust. UVA doesn’t cause immediate redness, so it’s harder to measure in short trials, and most PL studies haven’t been designed to isolate UVA effects cleanly.

The antioxidant skincare evidence has a parallel problem: antioxidants reduce oxidative stress markers, but reducing a biomarker isn’t the same as preventing a disease outcome. PL’s oral version faces the same epistemological gap.

None of this makes PL useless. It makes it incomplete.

Who Might Actually Benefit

The most evidence-backed use cases for oral PL are:

People with photosensitive skin conditions. If you have polymorphic light eruption, solar urticaria, or lupus-related photosensitivity, adding PL as an adjunct to topical sunscreen has real clinical backing. This is where dermatologists are most likely to suggest it.

People with melasma. UV exposure — even incidental, low-level exposure — can trigger melasma flares. PL as a complement to strict topical sun protection has been studied in this context, and the results are modestly positive. It’s not a standalone treatment, but alongside broad-spectrum SPF 30+, it may offer an additional layer.

People who struggle with consistent topical reapplication. Not a pass to skip sunscreen — but if you’re someone who tends to miss spots or forgets to reapply, PL may provide a small buffer on high-exposure days. Small being the operative word.

High-altitude or high-UV-index environments. Climbers, skiers, and anyone spending extended time in intense UV conditions might find value in stacking PL with adequate topical protection. Adjunct, not replacement.

How It Fits Into a Realistic Routine

If you want to try PL, here’s how to think about it: it’s an antioxidant supplement that provides modest photoprotective benefits. Treat it the way you’d treat topical antioxidants — as a complement, not a substitute.

You still need:

• Broad-spectrum SPF 30 minimum, applied in the correct amount. How much sunscreen to apply matters more than most people realize — most people apply 25–50% of the tested dose, which means their effective SPF is much lower than the label claims.
• Reapplication every two hours in direct sun, or after swimming and sweating. An oral supplement does nothing to address the SPF you’ve sweated off. Reapplying over makeup has its own learning curve.
• UV-protective clothing, shade, and timing — physical avoidance remains the highest-evidence intervention there is.

PL doesn’t change any of that calculus. It adds on top of it.

Dosing in clinical trials has typically ranged from 240–480 mg daily, taken 30–60 minutes before sun exposure. Most commercial capsules standardize to 240 mg of the Fernblock extract. Higher doses haven’t been shown to be dramatically more effective, and very few serious adverse events have been reported in trial populations. It’s generally well-tolerated.

The Products That Are Actually Researched

Most PL research has used the Fernblock extract (from Cantabria Labs), which is what Heliocare licenses for its formulations. This matters because supplement regulation is loose — a generic “polypodium leucotomos” capsule from a random manufacturer may not contain the same standardized extract used in clinical trials.

If you’re going to try it, use a brand that specifies the Fernblock extract on the label.

Heliocare is the most studied commercial brand and widely available. Cantabria Labs is the source manufacturer behind most of the clinical research. Both use the standardized Fernblock extract. Either is a reasonable choice.

What to skip: any supplement that claims SPF equivalency above 4–5, promises cancer protection, or doesn’t specify the extract source. The more ambitious the claim, the further it’s straying from the evidence base.

A Note on Ingestible Sun Protection More Broadly

PL isn’t the only oral compound with photoprotective properties. Nicotinamide (a form of vitamin B3) has decent evidence for reducing actinic keratoses and nonmelanoma skin cancer risk in high-risk populations — arguably stronger endpoint data than PL. Beta-carotene and lycopene have been studied, with weaker results. Astaxanthin shows up in some supplements too, though the clinical data is thinner.

The ingestible beauty research landscape is full of ingredients with plausible mechanisms and insufficient endpoint data. PL is one of the more credible entries in that category, but “more credible than most supplements” is a low bar.

None of them replace topical sunscreen. All of them could, theoretically, add a marginal benefit on top of it. Whether that margin is worth the cost and the pill is a personal calculation.

Putting It All Together

Polypodium leucotomos is not a sunscreen pill. It’s an antioxidant supplement with real but limited photoprotective effects — roughly equivalent to an SPF of 3–4, with the most reliable data coming from UVB endpoints like erythema.

The evidence is most compelling for people with photosensitive conditions, melasma, or unusually high UV exposure who want an additional layer on top of real sun protection. For everyone else, the marginal benefit is small, and the gap left by skipping or skimping on topical SPF is not something PL closes.

Use broad-spectrum sunscreen. Apply enough of it. Reapply. If you want to add PL on top of that during summer, the data supports it as a supplement in the literal sense — additive, not substitutive.

That’s the honest read. Anything that tells you otherwise is selling something.

---

For more on building a sun-safe routine, see our guides on next-generation UV filters and the best Korean sunscreens for 2026.